{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T15:06:53Z","timestamp":1788793613893,"version":"build-2803163510"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.amjms.2025.07.006","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:29:25Z","timestamp":1752625765000},"page":"377-382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome"],"prefix":"10.1016","volume":"370","author":[{"given":"Lawrence B.","family":"Afrin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard B.","family":"Weinstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tania T.","family":"Dempsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Aschenbrenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetlana","family":"Blitshteyn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill R.","family":"Schofield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2025.07.006_bib0001","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.amjms.2016.12.013","article-title":"Characterization of mast cell activation syndrome","volume":"353","author":"Afrin","year":"2017","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.amjms.2025.07.006_bib0002","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1007\/s00210-023-02545-y","article-title":"A survey of the currently known mast cell mediators with potential relevance for therapy of mast cell-induced symptoms","volume":"396","author":"Molderings","year":"2023","journal-title":"Naunyn Schmiedeb Arch Pharmacol"},{"key":"10.1016\/j.amjms.2025.07.006_bib0003","unstructured":"Ibelgaufts H. \u201cMast cells\u201d in COPE: cytokines and cells online pathfinder encyclopaedia, 2025. Available at https:\/\/www.cells-talk.com\/cope.cgi?key=mast%20cells (accessed May 18, 2025)."},{"key":"10.1016\/j.amjms.2025.07.006_bib0004","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1080\/00365520701245744","article-title":"Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder","volume":"42","author":"Molderings","year":"2007","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.amjms.2025.07.006_bib0005","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00251-010-0474-8","article-title":"Comparative analysis of mutation of tyrosine kinase Kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects","volume":"62","author":"Molderings","year":"2010","journal-title":"Immunogenetics"},{"key":"10.1016\/j.amjms.2025.07.006_bib0006","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.critrevonc.2014.09.001","article-title":"The genetic basis of mast cell activation disease - looking through a glass darkly","volume":"93","author":"Molderings","year":"2015","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.amjms.2025.07.006_bib0007","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s00251-017-0981-y","article-title":"Mutational profiling in the peripheral blood leukocytes of patients with systemic mast cell activation syndrome using next-generation sequencing","volume":"69","author":"Altm\u00fcller","year":"2017","journal-title":"Immunogenetics"},{"key":"10.1016\/j.amjms.2025.07.006_bib0008","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-04-496448","article-title":"Comprehensive mutational profiling in advanced systemic mastocytosis","volume":"122","author":"Schwaab","year":"2013","journal-title":"Blood"},{"issue":"supp 1s","key":"10.1016\/j.amjms.2025.07.006_bib0009","first-page":"S66","article-title":"The detection of novel KIT mutations in mastocytosis","volume":"133","author":"Chan","year":"2013","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.amjms.2025.07.006_bib0010","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1111\/ced.12000","article-title":"Distinct signalling pathways for mutated KIT(V560G) and KIT(D816V) in mastocytosis","volume":"38","author":"Chan","year":"2013","journal-title":"Clin Exp Dermatol"},{"issue":"supp 1s","key":"10.1016\/j.amjms.2025.07.006_bib0011","first-page":"S66","article-title":"Genetic background of mastocytosis, a synopsis of cooperative studies conducted by ECNM","volume":"133","author":"Nedoszytko","year":"2013","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.amjms.2025.07.006_bib0012","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1200\/JCO.2010.29.8711","article-title":"Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies","volume":"29","author":"Tefferi","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.amjms.2025.07.006_bib0013","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood-2011-01-331678","article-title":"Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression","volume":"118","author":"Klampfl","year":"2011","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.amjms.2025.07.006_bib0014","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4085.4085","article-title":"Genome-wide molecular portrait of aggressive systemic mastocytosis and mast cell leukemia depicted by whole exome sequencing and copy number variation analysis","volume":"126","author":"Soverini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.amjms.2025.07.006_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.intimp.2019.02.041","article-title":"Berberine suppresses mast cell-mediated allergic responses via regulating fc\u025bri-mediated and MAPK signaling","volume":"71","author":"Fu","year":"2019","journal-title":"Int Immunopharmacol"},{"issue":"6","key":"10.1016\/j.amjms.2025.07.006_bib0016","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/1744666X.2023.2200936","article-title":"Mast cell activation: beyond histamine and tryptase","volume":"19","author":"Theoharides","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"10.1016\/j.amjms.2025.07.006_bib0017","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/biof.1726","article-title":"Long-COVID syndrome-associated brain fog and chemofog: luteolin to the rescue","volume":"47","author":"Theoharides","year":"2021","journal-title":"Biofactors"},{"issue":"Pt A","key":"10.1016\/j.amjms.2025.07.006_bib0018","article-title":"Oral berberine ameliorates high-fat diet-induced obesity by activating TAS2Rs in tuft and endocrine cells in the gut","volume":"311","author":"Sun","year":"2022","journal-title":"Life Sci"},{"key":"10.1016\/j.amjms.2025.07.006_bib0019","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00210-016-1247-1","article-title":"Pharmacological treatment options for mast cell activation disease","volume":"389","author":"Molderings","year":"2016","journal-title":"Naunyn Schmiedeb Arch Pharmacol"},{"key":"10.1016\/j.amjms.2025.07.006_bib0020","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3109\/07853890.2016.1161231","article-title":"Often seen, rarely recognized: mast cell activation disease\u2013a guide to diagnosis and therapeutic options","volume":"48","author":"Afrin","year":"2016","journal-title":"Ann Med"},{"key":"10.1016\/j.amjms.2025.07.006_bib0021","doi-asserted-by":"crossref","first-page":"701","DOI":"10.12968\/jowc.2022.31.8.701","article-title":"The role of mast cells in cellular modifications evoked by Exendin-4 in treated wounds: a preclinical study","volume":"31","author":"Paroli","year":"2022","journal-title":"J Wound Care"},{"key":"10.1016\/j.amjms.2025.07.006_bib0022","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1471-230X-12-30","article-title":"Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neurons","volume":"12","author":"Voss","year":"2012","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10.1016\/j.amjms.2025.07.006_bib0023","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11154-014-9304-x","article-title":"Inflammation in sleep apnea: an update","volume":"16","author":"Unnikrishnan","year":"2015","journal-title":"Rev Endocr Metab Disord"},{"key":"10.1016\/j.amjms.2025.07.006_bib0024","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.amjms.2025.07.006_bib0025","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.immuni.2021.12.013","article-title":"Inflammation in obesity, diabetes, and related disorders","volume":"55","author":"Rohm","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.amjms.2025.07.006_bib0026","doi-asserted-by":"crossref","first-page":"199","DOI":"10.5114\/pjp.2016.63770","article-title":"Are mast cells important in diabetes?","volume":"67","author":"Kempuraj","year":"2016","journal-title":"Pol J Pathol"},{"key":"10.1016\/j.amjms.2025.07.006_bib0027","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1002\/stem.523","article-title":"Adipose tissue as a dedicated reservoir of functional mast cell progenitors","volume":"28","author":"Poglio","year":"2010","journal-title":"Stem Cells"},{"issue":"8","key":"10.1016\/j.amjms.2025.07.006_bib0028","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1002\/dmrr.1272","article-title":"Mast cell stabilization: novel medication for obesity and diabetes","volume":"27","author":"Wang","year":"2011","journal-title":"Diabetes Metab Res Rev"},{"issue":"9","key":"10.1016\/j.amjms.2025.07.006_bib0029","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.tips.2011.05.005","article-title":"Mast cells squeeze the heart and stretch the gird: their role in atherosclerosis and obesity","volume":"32","author":"Theoharides","year":"2011","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.amjms.2025.07.006_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0076241","article-title":"Familial occurrence of systemic mast cell activation disease","volume":"8","author":"Molderings","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.amjms.2025.07.006_bib0031","series-title":"Proceedings of the EDS ECHO Summit","article-title":"Immune dysfunction, both mast cell activation disorders and primary immune deficiency, is common among patients with hypermobile spectrum disorder (HSD) or hypermobile type Ehlers Danlos Syndrome (hEDS)","author":"Maitland","year":"2020"},{"key":"10.1016\/j.amjms.2025.07.006_bib0032","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.trsl.2016.01.003","article-title":"Mast cell activation disease and the modern epidemic of chronic inflammatory disease","volume":"174","author":"Afrin","year":"2016","journal-title":"Transl Res"},{"key":"10.1016\/j.amjms.2025.07.006_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1148209","article-title":"Glucagon-like peptide-1: a multi-faceted anti-inflammatory agent","volume":"14","author":"Mehdi","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.amjms.2025.07.006_bib0034","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.amjms.2025.07.006_bib0035","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediat Inflamm"},{"issue":"4","key":"10.1016\/j.amjms.2025.07.006_bib0036","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1053\/j.ackd.2021.04.002","article-title":"Glucagon-like peptide-1 receptor agonists-use in clinical practice","volume":"28","author":"Tric\u00f2","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.amjms.2025.07.006_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","volume":"186","author":"Kopp","year":"2022","journal-title":"Pharmacol Res"},{"issue":"2","key":"10.1016\/j.amjms.2025.07.006_bib0038","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s13679-023-00506-3","article-title":"GLP-1 receptor agonists in obese patients with inflammatory bowel disease: from molecular mechanisms to clinical considerations and practical recommendations for safe and effective use","volume":"12","author":"Arvanitakis","year":"2023","journal-title":"Curr Obes Rep"},{"issue":"40","key":"10.1016\/j.amjms.2025.07.006_bib0039","doi-asserted-by":"crossref","first-page":"14821","DOI":"10.3748\/wjg.v20.i40.14821","article-title":"Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation","volume":"20","author":"Wang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.amjms.2025.07.006_bib0040","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/COPD.S393323","article-title":"The role of glucagon-like peptide-1 receptor agonists in chronic obstructive pulmonary disease","volume":"18","author":"Wang","year":"2023","journal-title":"Int J Chron Obs Pulmon Dis"},{"issue":"2","key":"10.1016\/j.amjms.2025.07.006_bib0041","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1177\/2042018814543483","article-title":"Effect of glucagon-like peptide-1 receptor agonists in patients with psoriasis","volume":"5","author":"Al-Badri","year":"2014","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.amjms.2025.07.006_bib0042","doi-asserted-by":"crossref","DOI":"10.1016\/j.ophtha.2025.01.016","article-title":"Glucagon-like peptide-1 receptor agonist impact on chronic ocular disease including age-related macular degeneration","author":"Allan","year":"2025","journal-title":"Ophthalmology"},{"issue":"17","key":"10.1016\/j.amjms.2025.07.006_bib0043","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jacc.2024.08.007","article-title":"The effect of semaglutide on mortality and COVID-19-related deaths: an analysis from the SELECT trial","volume":"84","author":"Scirica","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.amjms.2025.07.006_bib0044","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1080\/14740338.2021.1970744","article-title":"The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism","volume":"20","author":"Banerjee","year":"2021","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.amjms.2025.07.006_bib0045","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ijid.2020.09.016","article-title":"Covid-19 hyperinflammation and post-Covid-19 illness may be rooted in mast cell activation syndrome","volume":"100","author":"Afrin","year":"2020","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.amjms.2025.07.006_bib0046","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ijid.2021.09.043","article-title":"Mast cell activation symptoms are prevalent in Long-COVID","volume":"112","author":"Weinstock","year":"2021","journal-title":"Int J Infect Dis"},{"issue":"5\u20136","key":"10.1016\/j.amjms.2025.07.006_bib0047","first-page":"20","article-title":"Unintended benefit of GLP-1 treatment for obesity: resolution of chronic systemic mastocytosis symptoms","volume":"20","author":"Woodman","year":"2023","journal-title":"Bariatr Times"},{"issue":"2","key":"10.1016\/j.amjms.2025.07.006_bib0048","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1515\/dx-2020-0005","article-title":"Diagnosis of mast cell activation syndrome: a global \u201cconsensus-2\u2033","volume":"8","author":"Afrin","year":"2020","journal-title":"Diagnosis"},{"key":"10.1016\/j.amjms.2025.07.006_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2021.102003","article-title":"Glucagon-like peptide 1 receptor (GLP-1R) agonist relieved asthmatic airway inflammation via suppression of NLRP3 inflammasome activation in obese asthma mice model","volume":"67","author":"Hur","year":"2021","journal-title":"Pulm Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.amjms.2025.07.006_bib0050","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1111\/apt.18138","article-title":"Use of glucagon-like peptide-1 receptor agonists for type 2 diabetes mellitus and outcomes of inflammatory bowel disease","volume":"60","author":"Desai","year":"2024","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.amjms.2025.07.006_bib0051","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1080\/00365521.2022.2041084","article-title":"Pain relief and pain intensity response to GLP-1 receptor agonist ROSE-010 in irritable bowel syndrome; clinical study cross-analysis with respect to patient characteristics","volume":"57","author":"Touny","year":"2022","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.amjms.2025.07.006_bib0052","article-title":"Mast cell activation syndrome and the triad of MCAS, POTS, and hypermobile EDS","author":"Weinstock","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.amjms.2025.07.006_bib0053","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11894-023-00909-1","article-title":"Getting the BS out of irritable bowel syndrome with diarrhea (IBS-D): let\u2019s make a diagnosis","volume":"26","author":"Frissora","year":"2024","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.amjms.2025.07.006_bib0054","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bbi.2015.07.002","article-title":"Mast cell activation disease: an underappreciated cause of neurologic and psychiatric symptoms and diseases","volume":"50","author":"Afrin","year":"2015","journal-title":"Brain Behav Immun"},{"issue":"11","key":"10.1016\/j.amjms.2025.07.006_bib0055","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.3390\/jpm13111562","article-title":"Neuropsychiatric manifestations of mast cell activation syndrome and response to mast-cell-directed treatment: a case series","volume":"13","author":"Weinstock","year":"2023","journal-title":"J Pers Med"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925011061?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925011061?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T18:42:52Z","timestamp":1758048172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962925011061"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S0002962925011061"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2025.07.006","relation":{},"ISSN":["0002-9629"],"issn-type":[{"value":"0002-9629","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2025.07.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc. on behalf of Southern Society for Clinical Investigation.","name":"copyright","label":"Copyright"}]}}